Is Sun Pharma Advanced Research Company a Good Buy After Its Q1 FY27 Results?
- September 7, 2026
- Posted by: Lakshit Sharma
- Category: Market
Sun Pharma Advanced Research Company share price around Rs 201. 30.4% below 52-week high of Rs 289. Q1 FY27 revenue Rs 64 crore, up 238.6% YoY. loss of Rs 21 crore. PE 4x.
Quick Answer
Sun Pharma Advanced Research Company continued to report a net loss in Q1 FY27, at Rs 21 crore, though the loss narrowed year on year as revenue grew to Rs 64 crore. The Sun Pharma Advanced Research Company share price near Rs 201 reflects a business still working toward profitability, so this is best treated as a turnaround watch rather than a value buy on this quarter’s numbers.
The Sun Pharma Advanced Research Company share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Sun Pharma Advanced Research Company is a drug discovery and research entity affiliated with the Sun Pharma group, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 64 crore, up 238.6% year on year, while the company reported a net loss of Rs 21 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Sun Pharma Advanced Research Company share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Sun Pharma Advanced Research Company share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Sun Pharma Advanced Research Company Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 64 crore | Rs 19 crore | 238.6% |
| EBITDA | -Rs 10 crore | -Rs 43 crore | 75.9% |
| Operating Margin | -25.9% | -445.4% | NA |
| Profit Before Tax | -Rs 21 crore | -Rs 52 crore | 60.1% |
| Net Profit / (Loss) | -Rs 21 crore | -Rs 52 crore | 59.9% |
Sun Pharma Advanced Research Company Q1 FY27 Performance Analysis
Check Sun Pharma Advanced Research Company Fundamentals on Univest Screener
Revenue growth of 238.6% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmaceutical research and drug development sector.
The loss for the quarter came in narrower year on year at -Rs 21 crore, against -Rs 52 crore a year ago. Revenue grew 238.6% in the same period, so the business is scaling, but profitability has not yet followed, which is the central issue for anyone tracking the Sun Pharma Advanced Research Company share price for a turnaround.
On a sequential basis, revenue moved down 96.6% sequentially from Rs 1,855 crore in the March 2026 quarter and the net loss moved down 101.2% sequentially from Rs 1,761 crore in the prior quarter, giving a fuller picture of the trend behind the Sun Pharma Advanced Research Company share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Sun Pharma Advanced Research Company’s revenue grew 238.6% year on year this quarter, taking the quarterly base to Rs 64 crore in a pharmaceutical research and drug development business that remains sensitive to demand and pricing cycles that ultimately feed through to the Sun Pharma Advanced Research Company share price.
Margin Movement
EBITDA rose 75.9% to -Rs 10 crore, and operating margin moved to -25.9% from -445.4% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Sun Pharma Advanced Research Company’s debt-to-equity ratio stands at 0.42, a level worth monitoring given the quarter’s margin trend.
Valuation Context
The stock trades at a PE of 4.2x, below the industry average of 38.0x, which is worth factoring into any read of whether the Sun Pharma Advanced Research Company share price is expensive or reasonably priced.
Dividend Details
No interim dividend was declared alongside Sun Pharma Advanced Research Company’s Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Sun Pharma Advanced Research Company share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Sun Pharma Advanced Research Company Share Price Outlook for FY27
Sun Pharma Advanced Research Company remains a turnaround story rather than a steady compounder for now. Revenue growth is encouraging, but the pace at which losses shrink over the coming quarters will matter more to the Sun Pharma Advanced Research Company share price than the topline trend alone.
A clear, sustained narrowing of losses over the next two to three quarters would be the strongest signal for the Sun Pharma Advanced Research Company share price, while a stall or reversal in that trend would call for more caution.
Sun Pharma Advanced Research Company Stock Performance
Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company’s live share price and get daily stock updates.
The Sun Pharma Advanced Research Company share price was trading around Rs 201 as results season played out in late August 2026, roughly 30.4% below its 52-week high of Rs 289 and well above its 52-week low of Rs 108. Promoter holding stood at 65.7% as of the June 2026 quarter.
The Sun Pharma Advanced Research Company share price has moved without much drama on this result, consistent with a quarter that did not materially change the investment case either way. On profitability ratios, the company reports a return on equity of 116.01% and a book value of around Rs 41 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Profitability Risk
The quarter’s profit trend is the clearest risk here. Until Sun Pharma Advanced Research Company shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.
Sector and Demand Risk
As a pharmaceutical research and drug development business, Sun Pharma Advanced Research Company’s results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Sun Pharma Advanced Research Company share price well before the next result.
Execution Risk
Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
Conclusion
Sun Pharma Advanced Research Company remains loss-making in Q1 FY27, with the loss narrowing year on year alongside revenue growth of 238.6%. The Sun Pharma Advanced Research Company share price suits investors comfortable with a turnaround story more than those looking for near-term profitability, and position sizing should reflect that risk.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Sun Pharma Advanced Research Company Q1 FY27 Results
What were Sun Pharma Advanced Research Company’s Q1 FY27 results?
Ans. Sun Pharma Advanced Research Company reported Q1 FY27 revenue of Rs 64 crore, up 238.6% year on year, with a net loss of Rs 21 crore.
Is Sun Pharma Advanced Research Company a good buy after its Q1 FY27 results?
Ans. Sun Pharma Advanced Research Company’s profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.
What is the Sun Pharma Advanced Research Company share price today?
Ans. The Sun Pharma Advanced Research Company share price was trading around Rs 201 in late August 2026, about 30.4% below its 52-week high of Rs 289 and well above its 52-week low of Rs 108.
What is Sun Pharma Advanced Research Company’s revenue and profit for Q1 FY27?
Ans. Sun Pharma Advanced Research Company reported revenue of Rs 64 crore and a net loss of Rs 21 crore for the quarter ended June 30, 2026.
Did Sun Pharma Advanced Research Company declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Sun Pharma Advanced Research Company’s Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Sun Pharma Advanced Research Company’s PE ratio and is it expensive?
Ans. The Sun Pharma Advanced Research Company share price trades at a trailing PE of 4.2x, against an industry average of 38.0x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Sun Pharma Advanced Research Company investors right now?
Ans. The quarter’s profit trend is the clearest risk here. Until Sun Pharma Advanced Research Company shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
What is Sun Pharma Advanced Research Company’s promoter shareholding?
Ans. Promoter holding in Sun Pharma Advanced Research Company stood at 65.7% as of the June 2026 quarter.